Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,704.00+4.80%ETH$2,426.56+7.03%GOLD$4,092.80+0.49%OIL$88.04-0.09%
Smart Investors Daily
SID Premium
SX

NASDAQ · SXTP

60 Degrees Pharmaceuticals, Inc.

Healthcare · Biotechnology

$1.01

Down-$0.07 (-7.18%)

Updated Nov 4, 2026, 10:33 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.82M
P/E ratio
-0.4
Dividend yield
0.00%
52-week range
$0.59 – $3.55
Volume
71.9K
Avg. volume
131.1K

Price performance · SXTP

SXTP price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

SXTP closed at $1.01 after 21 trading sessions, down 9.01% for the selected period.

Last close
$1.01
Period change
-9.01%
Period low
$0.74
Period high
$1.11
Daily close
View OHLC price history
SXTP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.9313$1.02$0.87$1.0171.9K
Nov 2, 2026$0.9482$0.9482$0.8267$0.905746.82K
Oct 30, 2026$0.9436$0.9692$0.90$0.9473.53K
Oct 29, 2026$0.802$1.00$0.799$0.9475358.27K
Oct 28, 2026$0.7856$0.9876$0.75$0.8472.01M
Oct 27, 2026$0.8686$0.8724$0.588$0.7416.42M
Oct 26, 2026$0.86$0.8885$0.8238$0.867919.6K
Oct 23, 2026$0.8205$0.9296$0.8205$0.870113.07K
Oct 22, 2026$0.8714$0.9144$0.85$0.875917.68K
Oct 21, 2026$0.9409$0.9499$0.8702$0.8924.69K
Oct 20, 2026$0.8263$0.9999$0.8115$0.922234.28K
Oct 19, 2026$0.861$0.8996$0.82$0.827340.51K
Oct 16, 2026$0.90$0.912$0.85$0.855413.55K
Oct 15, 2026$0.88$0.8999$0.835$0.898937.34K
Oct 14, 2026$0.91$0.9411$0.8774$0.880253.28K
Oct 13, 2026$0.8874$0.942$0.875$0.9037.47K
Oct 12, 2026$0.9386$0.9627$0.8909$0.915638.24K
Oct 9, 2026$0.96$0.9959$0.91$0.965442.06K
Oct 8, 2026$1.02$1.0799$0.96$0.972593.14K
Oct 7, 2026$1.06$1.16$1.0081$1.10154.3K
Oct 6, 2026$1.07$1.1961$0.892$1.112.45M

Latest SXTP news

The latest Smart Investors Daily articles mentioning SXTP.

Stock researchCompany · Overview

SXTP research

Overview

Company profile and research snapshot.

Company profile

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
SXTP recent ratings
DateFirmRatingTarget
May 22, 2026Ascendiant CapitalBuy—
May 20, 2026HC Wainwright & Co.Neutral—
Apr 9, 2026Ascendiant CapitalBuy—
Jan 27, 2026HC Wainwright & Co.Buy—
Nov 28, 2025Ascendiant CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome

Company plans to explore botanical approval pathways before initiating a prescription drug development programWASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, today announced expansion of its vector-borne disease research portfolio through a sponsored research agreement with The University of Southern Mississippi (USM) to assess the therapeu

Yahoo · Oct 27, 2026

60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients

All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR testsFour of five completed patients (80%) were negative on highly sensitive post-treatment NAT testingResults reinforce favorable retreatment-free outcomes reported with tafenoquine–atovaquone regimensTwo additional patients remain on treatment, bringing total enrollment to seven; study remains open pending potential discussions with FDA WASHINGTON, Oct. 2

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By